MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial
Francesco Giganti(University College Hospital), Alex Kirkham(University College London Hospitals NHS Foundation Trust), Brandon Whitcher(Royal Marsden NHS Foundation Trust), Mathias Winkler(National Health Service), Simon Bott(Prostate Cancer Research), Giulio Gambarota(Inserm), Charles Jameson(Royal London Hospital), Mark Emberton(University College London), Nicola L. Robertson(University College London Hospitals NHS Foundation Trust), Ramiro Castro(GlaxoSmithKline (United States)), Clare Allen(St Peter's Hospital), Neil McCartan(University College London), Caroline M. Moore(University College London Hospitals NHS Foundation Trust)
Cited by 36
Related Papers
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
|The Lancet|2017|3.2k
A Resilient, Low-Frequency, Small-World Human Brain Functional Network with Highly Connected Association Cortical Hubs
|Journal of Neuroscience|2006|2.5k
An Introduction to Wavelets and Other Filtering Methods in Finance and Economics
|Elsevier eBooks|2002|1.1k
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694